Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)

Orion Corporation, Orion Pharma227 enrolled

Overview

The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with chronic obstructive pulmonary disease (COPD).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

227

Conditions

Asthma Chronic Obstructive Pulmonary Disease

Interventions

Easyhaler type ADEVICE

Easyhaler type A inhaler, 3 consecutive inhalations

Easyhaler type BDEVICE

Easyhaler type B inhaler, 3 consecutive inhalations

Diskus inhalerDEVICE

Diskus inhaler, 3 consecutive inhalations

Eligibility

Sex: ALLMin age: 4 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent (IC) obtained * Documented diagnosis of asthma and/or COPD * Age: 4 years and above Exclusion Criteria: * Any severe chronic respiratory disease other than asthma or COPD * Acute respiratory infection * Any medical condition that in the opinion of the investigator would endanger the subject if he/she participates in the study

Locations (5)

Lasnamäe Medicum

Tallinn, Estonia

Children's Clinic of Tartu, Allergy Centre

Tartu, Estonia

Tartu University Hospital, Lung Clinic

Tartu, Estonia

Jorvi Hospital HUS

Espoo, Finland

Turku University Hospital

Outcomes

Primary Outcomes

Peak inspiratory flow rate through the placebo Easyhaler and Diskus inhalers

Time frame: 1 day

Secondary Outcomes

The inspiratory volume through the placebo Easyhaler and Diskus inhalers will be measured at the same time with the peak inspiratory flow rate

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.